Method for producing lysozyme-containing biologically active additive

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to a method for the preparation of a lysozyme-containing biologically active additive, comprising the reception and preparation of eggs, separation of egg contents into protein and yolk, introduction of salt into the protein salt at a concentration of 0.4 % and acid ascorbic concentration of 7 %, heating to a temperature of 65–70 °C for 15–20 minutes, filtration, drying of the hydrolyzate in the vibro-boiling layer and subsequent packing.

EFFECT: invention makes it possible to obtain lysozyme with increased yield.

1 cl, 2 ex, 4 dwg

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention deals with application of composition, which includes hydrolysate of pea protein and/or peptide for obtaining composition for treatment and/or prevention of infection Helicobacter pylori (versions), as well as such compositions (versions). Characterised compositions include lipid, protein and carbohydrate component, in which protein component includes protein source, which consists of pea protein hydrolysate, obtained by hydrolysis with protease, different from chymotrypsin, or from peptides, selected from group, which consists of Xaan-Asp-Phe-Leu-Glu-Asp-Ala-Phe-Asn-Val-Asn-Arg-Xaam and Xaan-Glu-Leu-Ala-Phe-Pro-Gly-Ser-Ala-Gln-Glu-Val-Asp-Arg-Xaam, where each Xaa independently can be any amino acid, and n and m are integer numbers, independently varying from 0-10, where peptide is contained in pea protein hydrolysate, or from both.

EFFECT: claimed inventions make it possible to treat or prevent diseases, caused by Helicobacter pylori infection, and/or diseases, associated with infection Helicobacter pylori in mammals.

17 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: enteric therapy is started intraoperatively with introducing a glucose-electrolyte mixture 100 ml by means of a silicone probe inserted behind a gastroentero- or duodenoenteroanastomosis. On the first postoperative day, the amount of the fractionally introduced GEM is increased to 300.0 ml at 60 ml/hour, which is followed by enabling a passive outflow of the intestinal content. If the intestinal peristalsis tends to recover from the second postoperative day, a nutritional probe therapy is added with Nutrison Advanced Diason isocaloric formula 498 ml that is 10.0 kcal/kg at 60 ml/hour, which is followed by enabling the passive outflow of the intestinal content. If the probe spillage makes more than 50% of the amount of the nutritional formula administered for 1 hour, the previous rate of the washout intestinal infusion is maintained. If the nutritional formula is digested, the amount of Nutrison Advanced Diason isocaloric formula is increased to 700-800 ml/day. If the patient has a compensated glucose profile on the 4th postoperative day, the amount of the tube feeding is increased to 1398 ml of Nutrison Standard that is 15.0 kcal/kg with the infusion rate to be increased to 90 ml/hour. On the fifth postoperative day, the patients having a good tube feeding tolerance are given with Nutrison Energy hypercaloric hypernitrogenous polymer nutritional formula with dietary fibres in an amount of 1000.0 ml that is 20.0 kcal/kg with keeping the infusion rate the same. On the sixth day, the patient starts unassisted enteric nutrition and is nutritionally supported with Nutridrink hypercaloric nutritional formula in an amount of 200.0 ml 2 or 3 times a day by sipping.

EFFECT: improving the trophological values that causes reducing the number of postoperative complications, mortality and length of staying in hospital by the optimum regimen of treatment.

6 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. A sedative composition with reducing affectivity accompanying oestrus for dogs and cats contains in one dose per 10 kg of animal's body weight: theanine - from 5 to 100 mg, tryptophane - from 2 to 16 mg.

EFFECT: composition normalises the animals' behaviour for 30 minutes - 1 hour after application.

6 ex

FIELD: biotechnology.

SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.

EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.

4 cl, 5 ex

FIELD: medicine.

SUBSTANCE: in the process of preoperative preparation imunofan is introduced to a patient intramuscularly in a dose of 1 ml one time per day. After that, laparoscopy with revision of the abdominal cavity organs, opening of the omental bursa and its washing with solutions of antiseptics, and formation of the external cholecystoma are performed. Intraoperatively at the stage of the omental bursa drainage and before performing cholecyctomy, into the stomach introduced is a thin probe for enteral nutrition, through which early intraoperative nutrition is realised by introduction of liquid food "Diason" at a rate of 30 ml/hour in an amount of 450-500 ml on the first day of the postoperative period. In the postoperative period introduction of imunofan in the same dose is continued for 9 days. Introduction of "Diason" food through the thin probe is also continued on the second day of the postoperative period at a rate of 30 ml/hour in an amount of 450-500 ml, on the third day at a rate of 45-60 ml/hour in an amount of 700-750 ml, on 4 and 5 day at a rate of 80-90 ml/hour in an amount of 950-1000 ml, from 6 to 9 days at a rate of 125-150 ml/hour in an amount of 1500-2000 ml. On the 10-th day after operation the probe of enteral nutrition is removed. After that, a seeping type of nutrition is realised, in the process of which a drink supportan or nutridrink is introduced to the patient in an amount of 200 ml 3-4 times per day until complete recovery of the trophological status.

EFFECT: method provides prophylaxis of purulent-inflammatory complications due to the prevention of impairment of cellular and humoral immunity and sufficient correction of the trophological status, contributing to a considerable increase of life quality of the operated patient.

3 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposed N-end fragment of soluble suppressor of immune response with the length of 21 amino-acids, which has sequence of amino-acids as per Seq ID NO: 1, allowing to promote formation of regulatory T-lymphocytes, as well as a promotion method of formation of regulatory T-lymphocytes with N-end fragment of soluble suppressor of immune response with Seq ID NO: 1, at its introduction with the concentration of 0.1-50 microgram/ml.

EFFECT: invention can be used for propagation of regulatory T-lymphocytes obtained from a patient suffering autoimmune disease, for the purpose of further injection of the obtained T-lymphocytes into the body of the patient.

3 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology and can be applied for treatment of traumatic and dystrophic injuries of eye cornea. For this purpose peptide fragments of protein S100b - SP2 and/or SP3 in concentrations 10-6 M are introduced in conjunctive cavity or in endonasal way. Introduction is realised daily two times per day during 10 days.

EFFECT: method ensures fast and high-quality restoration of injured zone of cornea due to stimulation of regenerative-reparative processes in cornea.

3 ex, 2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biochemistry. A biomass of the gram-negative bacteria Salmonella typhi fam. Enterobacteriacea is prepared. A cell wall peptidoglycane (CWP) of the bacteria is recovered by biomass extraction in 45% aqueous phenol at temperature 70-90°C or in aqueous solution of ionic or non-ionic detergents at temperature 37-100°C. That is followed by preparative enzymatic hydrolysis for insoluble CWP cleavage with the use of lysozyme at pH 4.5 - 8.9 and temperature 10 - 37°C. Simultaneously, a pharmacologically acceptable mixture of substances is removed by dialysis from the reaction mixture with the use of semipermeable membranes for ultrafiltration with cut-off size up to 5 kDa. The mixture of substances is also recovered by means of column gel-chromatography, particularly preparative gel chromatography on Sephadex or TSK gel columns. The end product yield is 320 mg.

EFFECT: method enables producing the pharmacologically acceptable mixture of substances containing the following ingredients: β-N-acetyl-D-glucosaminyl-(1→4)-N-acetyl-D-muramoyl-(L-alanyl-D-isoglutaminyl-meso-diaminopimelic acid) (GMtri); β-N-acetyl-D-glucosaminyl-(1→4)-N-acetyl-D-muramoyl-(L-alanyl-D-isoglutaminyl-meso-diaminopimeloyl-D-alanine) (GMtetra); and GMtetra dimer (diGMtetra) wherein a bond of monomer residues of GMtetra is enabled by a carboxyl group of terminal D-alanine of one GMtetra residue and ω-aminogroup of meso-diaminopimelic acid of the other GMtetra residue with the coupled tetrapeptide resides positioned in various polysaccharide chains.

4 cl, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of invention refers to ophthalmic compositions containing protease inhibition peptide substrates. The ophthalmic compositions contains a peptide substrate in a solution in the amount of approximately 0.01 wt/vol. % to 10 wt/vol. %, and said substrate is specified in a group consisting of gelatin, ovomacroglobulin, collagen and casein in an ophthalmically acceptable carrier. The composition additionally contains galactomannan and borate. The invention also describes a method for using the composition for treating dry eye.

EFFECT: group of invention provides higher viability and lower water loss of corneal epitheliocytes.

12 cl, 12 dwg, 11 ex

FIELD: medicine.

SUBSTANCE: composition for treatment and/or prevention of infection with gastrointestinal pathogens and/or disease of mammals, associated with infection by said pathogens, contains lipid, protein and hydrocarbon part, where lipid part provides from 5 to 50% of total number of calories, protein part provides from 5 to 50% of total number of calories and carbohydrate part provided from 15 to 90% of total number of calories. Protein part contains: (i) pea protein hydrolysate and (ii) at least one source of nitrogen, selected from the group, consisting of milk proteins, milk protein hydrolysate, egg protein and egg protein hydrolysate.

EFFECT: application of claimed composition in mixture composition makes it possible to increase efficiency of treatment or prevention of infection with gastrointestinal pathogens, in particular, Helicobacter pylori, or disease of mammals, associated with said pathogen infection.

1 ex, 1 tbl

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The product contains whey proteins -15÷20, egg protein - 10÷12, dry beestings - 4÷7, L-glutamine amino acid -1÷5, fructose - 6÷10, vegetal food fibres complex represented by a mixture of gum arabic and fructooligosaccharides taken at a weight ratio of (30-70):(70-30) 1÷5, creatine monohydrate - 3÷5, vitamin premix - 0.12÷0.15, mineral premix - 2.02÷2.05, flavouring additives - 0.48÷0.62 and maltodextrin - up to 100. The ratio of initial components is expressed in terms of wt %.

EFFECT: invention allows to manufacture a product with enhanced nutritive value, intensified anticatabolic, immunomodulating, detoxification and lipid-mobilising properties.

4 cl, 3 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The food composition for usage in food products for phenylketonuric children includes a dry egg product - 5-30 wt % in terms of dry substance and swelling maize starch - 70-95 wt % in terms of dry substance.

EFFECT: introduction of the food composition with an egg protein product into dishes recipes enhances the product nutritious value, has an immune-stimulating effect, allows to dose phenylalanine in alimentation of phenylketonuric children.

2 cl, 2 tbl, 3 ex

FIELD: food industry.

SUBSTANCE: method involves preliminary heating of native whole egg proteins at a temperature no more than 65°C during 2 - 15 minutes. The first stage of hydrolysis is performed using the first protease chosen from the group containing Bacillus amyloliquefaciens and Bacillus licheniformis bacterial proteases and their mixtures, trypsin and pancreatin. One performs an intermediate heating stage whereat the first hydrolysis product is heated up to a temperature no more than 75°C. The second stage of hydrolysis is performed using the second protease chosen from the group containing Bacillus licheniformis bacterial proteases, Aspergillus oryzae fungous proteases, trypsin and pancreatin and one proceeds with an inactivation stage whereat the second hydrolysis product is heated up to 85-90°C and maintained at this temperature during 30 minutes. Optionally Aspergillus oryzae fungous protease may be added in an amount of 10 - 60% during the intermediate heating stage; the Aspergillus oryzae fungous protease remainder is added after the intermediate heating stage.

EFFECT: invention allows to manufacture hypoallergenic proteins of whole egg.

3 cl, 2 dwg, 6 ex

FIELD: food industry.

SUBSTANCE: invention is related to poultry-processing industry. The method envisages separation of egg albumen from yolk, stirring albuminous mass, addition of an acid, heat treatment of the albuminous mixture and pasterurisation of the albumen product. The acid is represented by citric, lactic or malic acid or a mixture of these acids in an amount of 1.0 - 6.0% (by weight) in the form of a 5% water solution till the albuminous mixture pH is 4.5-6.1. Heat treatment of the albuminous mixture is implemented during 1-3 minutes till temperature is 60-70°C; then one separates the liquid phase. Then the coagulate is pasteurised at a temperature of 80-90°C during 10-20 minutes.

EFFECT: invention allows to preserve native properties of egg albumen and enhance the product quality.

1 tbl

The invention relates to the production of water of biologically active compositions based melt condensate resulting from the freeze-drying of protein products may be used in pharmaceuticals, cosmetics, food industry, etc
The invention relates to food industry, namely the production of biologically active additives to food, prevention of food containing such a BAD
The invention relates to food industry, namely the production of functional food additives on the basis of products of processing of eggs

FIELD: food industry.

SUBSTANCE: invention is related to poultry-processing industry. The method envisages separation of egg albumen from yolk, stirring albuminous mass, addition of an acid, heat treatment of the albuminous mixture and pasterurisation of the albumen product. The acid is represented by citric, lactic or malic acid or a mixture of these acids in an amount of 1.0 - 6.0% (by weight) in the form of a 5% water solution till the albuminous mixture pH is 4.5-6.1. Heat treatment of the albuminous mixture is implemented during 1-3 minutes till temperature is 60-70°C; then one separates the liquid phase. Then the coagulate is pasteurised at a temperature of 80-90°C during 10-20 minutes.

EFFECT: invention allows to preserve native properties of egg albumen and enhance the product quality.

1 tbl

FIELD: food industry.

SUBSTANCE: method involves preliminary heating of native whole egg proteins at a temperature no more than 65°C during 2 - 15 minutes. The first stage of hydrolysis is performed using the first protease chosen from the group containing Bacillus amyloliquefaciens and Bacillus licheniformis bacterial proteases and their mixtures, trypsin and pancreatin. One performs an intermediate heating stage whereat the first hydrolysis product is heated up to a temperature no more than 75°C. The second stage of hydrolysis is performed using the second protease chosen from the group containing Bacillus licheniformis bacterial proteases, Aspergillus oryzae fungous proteases, trypsin and pancreatin and one proceeds with an inactivation stage whereat the second hydrolysis product is heated up to 85-90°C and maintained at this temperature during 30 minutes. Optionally Aspergillus oryzae fungous protease may be added in an amount of 10 - 60% during the intermediate heating stage; the Aspergillus oryzae fungous protease remainder is added after the intermediate heating stage.

EFFECT: invention allows to manufacture hypoallergenic proteins of whole egg.

3 cl, 2 dwg, 6 ex

Up!